10-Q 1 g70018e10-q.txt MAXXIM MEDICAL, INC. 1 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended APRIL 29, 2001 -------------- ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . ------------ -------------- Commission File Number 333-92825 --------- MAXXIM MEDICAL, INC. ------------------------------------------------------------ (Exact name of registrant as specified in its charter) TEXAS 76-0291634 ------------------------------ ------------------------------------ State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 10300 49TH STREET NORTH, CLEARWATER, FLORIDA 33762 --------------------------------------------- --------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code .......... (727) 561-2100 -------------- Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate the number of shares outstanding of each of the issuer's classes of common stock: Class Outstanding at June 8, 2001 ----------------------------- ---------------------------- COMMON STOCK, $.001 PAR VALUE 30,165,161 2 MAXXIM MEDICAL, INC. INDEX

~~January~~Page ~~28,~~No. ~~October 29, 2001 2000~~ --------~~---~~ ~~-----------~~PART ~~(unaudited)~~I. ~~ASSETS~~Financial ~~Current~~Information ~~assets:~~Item ~~Cash and cash equivalents $ 933 $~~ 1~~,287~~. ~~Accounts~~Condensed ~~receivable,~~Consolidated ~~net~~Balance ofSheets ~~allowances~~as of ~~$3,560~~October ~~and $3~~29,~~526,~~ ~~respectively~~2000 ~~53,596~~and ~~46,256~~April ~~Inventory~~29, ~~net~~2001 ~~66,195~~2 ~~66,913~~Condensed ~~Other~~Consolidated ~~receivables~~Statements ~~15,024~~of ~~15,024~~Operations ~~Prepaid expenses and other 3,847 5,906 Assets held~~ for ~~sale~~the ~~18,388~~Fiscal ~~18,388~~Quarters ~~---------~~Ended ~~---------~~April ~~Total current assets 157~~30,~~983~~ ~~153,774~~2000 ~~Property~~ and ~~equipment~~April ~~106~~29,~~273~~ ~~103,952~~2001 ~~Less:~~3 ~~accumulated~~Condensed ~~depreciation~~Consolidated ~~(50,788)~~Statements ~~(47,206) --------- --------- 55,485 56,746 Goodwill, net~~ of ~~accumulated~~Cash ~~amortization~~Flows offor ~~$47,578~~the ~~and~~Fiscal ~~$46,508,~~Quarters ~~respectively~~Ended ~~110,030~~April ~~110~~30,~~969~~ ~~Other~~2000 ~~assets,~~and ~~net~~April 2529,~~903~~ ~~27,834~~2001 ~~---------~~4 ~~---------~~Notes ~~Total~~to ~~assets~~Condensed $Consolidated ~~349,401~~Financial $Statements ~~349,323~~5 ~~=========~~Item ~~=========~~2. ~~LIABILITIES AND SHAREHOLDERS~~Management's ~~EQUITY~~Discussion ~~(DEFICIT)~~and ~~Current~~Analysis ~~liabilities: Current maturities~~ of ~~long-term~~Results ~~debt $ 10,708 $ 10,688 Current maturities~~ of ~~capital~~Operations ~~leases~~ and ~~other~~Financial ~~long-term~~Condition ~~obligations~~17 ~~679~~Item 712 Accounts payable 49,173 47,505 Accrued liabilities 50,492 50,066 --------- --------- Total current liabilities 111,052 108,971 Long-term debt, net of current maturities 201,232 200,182 Senior subordinated discount notes 110,976 110,123 Senior discount notes 55,648 53,579 10 1/2% Senior subordinated notes 5 5 Capital leases and other long-term obligations, net of current maturities 3~~,611 3,728 --------- --------- Total liabilities 482,524 476,588 Shares with put rights ($~~.~~001~~ ~~par~~Quantitative ~~value common stock, 882,019 shares issued~~ and ~~outstanding)~~Qualitative ~~4,410~~Disclosures ~~4,410~~About ~~Commitments~~Market ~~and~~Risk ~~contingencies~~20 ~~Shareholders'~~PART ~~equity (deficit) Preferred Stock, $1~~II.00 ~~par~~Other ~~value,~~Information ~~10,000,000~~21 ~~shares~~Signatures authorized, none issued or outstanding -- -- Common Stock, $.001 par value, 40,000,000 shares authorized, 29,283,142 and 74,250,498 issued and outstanding, respectively 29 29 Additional paid-in capital (4,731) (4,731) Accumulated deficit (115,066) (107,964) Subscriptions receivable (2,974) (2,974) Accumulated other comprehensive loss (14,791) (16,035) --------- --------- Total shareholders' deficit (137,533) (131,675) --------- --------- Total liabilities and shareholders' equity (deficit) $ 349,401 $ 349,323 ========= =========22

1 3 PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS MAXXIM MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

~~Fiscal~~April ~~Quarter~~29, ~~Ended~~October 29, 2001 2000 ----------- ----------~~--------~~ ~~January~~(unaudited) 28ASSETS Current assets: Cash and cash equivalents $ 2,473 ~~January~~$ 301,287 ~~2001~~Accounts ~~2000~~receivable, net of allowances of $3,792 and $3,526, respectively 52,187 46,256 Inventory, net 81,654 66,913 Other receivables 2,561 15,024 Prepaid expenses and other 3,354 5,906 Assets held for sale 18,388 18,388 ---------- ---------- ~~Net~~Total ~~sales~~current $assets ~~123~~160,~~498~~617 $153,774 ~~122~~Property and equipment 106,~~828~~360 ~~Cost~~103,952 ofLess: ~~sales~~accumulated 93depreciation (52,~~820~~954) 89(47,~~897~~206) ---------- ---------- ~~Gross profit 29~~53,~~678~~406 3256,~~931~~746 ~~Selling~~Goodwill, ~~general~~net ~~and~~of ~~administrative~~accumulated ~~expenses~~amortization 21of $48,579 22and $46,~~529~~508, ~~Restructure~~respectively ~~charges~~108,979 ~~and~~110,969 ~~transition~~Other ~~expenses~~assets, --net 325,~~785~~635 27,834 ---------- ---------- ~~Income~~Total ~~from~~assets ~~operations~~$ 8348,~~099~~637 6$ 349,~~617~~323 ~~Interest~~========== ~~expense,~~========== ~~net~~LIABILITIES ~~(14,148)~~AND SHAREHOLDERS' EQUITY (~~11,252~~DEFICIT) ~~Other~~Current ~~income~~liabilities: ~~(expense)~~Current maturities of long-term debt $ 10,708 ~~net~~$ ~~(698)~~10,688 ~~(242)~~Current ~~Recapitalization~~maturities ~~expenses~~of capital leases and other long--term ~~(18~~obligations 1,~~697)~~210 712 Accounts payable 50,498 47,505 Accrued liabilities 45,010 50,066 ---------- ---------- ~~Loss~~Total ~~from~~current ~~continuing~~liabilities ~~operations~~107,426 ~~before~~108,971 ~~income~~Long-term ~~taxes~~debt, (6net of current maturities 206,~~747)~~732 ~~(23~~200,~~574)~~182 ~~Income~~Senior ~~tax~~subordinated ~~benefit~~discount notes 111,829 110,123 Senior discount notes 57,740 53,579 10 1/2% Senior subordinated notes 5 5 Capital leases and other long--term (obligations, net of current maturities 3,~~209)~~480 3,728 ---------- ---------- ~~Loss~~Total ~~from~~liabilities ~~continuing~~487,212 ~~operations~~476,588 Shares with put rights (6$.001 par value common stock,~~747~~ 882,019 shares issued and outstanding) ~~(20~~4,~~365~~410 4,410 Commitments and contingencies Shareholders' equity (deficit) ~~Income~~Preferred ~~from~~Stock, ~~discontinued~~$1.00 ~~operations~~par value, ~~net~~10,000,000 ofshares ~~tax~~authorized, ofnone ~~$56~~issued --or 87outstanding --~~-------~~ --~~-------~~ ~~Loss~~Common ~~before~~Stock, ~~extraordinary~~$.001 ~~item~~par (6value,~~747)~~ ~~(20~~40,~~278)~~000,000 ~~Extraordinary~~shares ~~item~~authorized, -29,283,142 ~~loss~~and ~~related~~29,283,142 toissued ~~early~~and ~~retirement~~outstanding, ofrespectively ~~debt~~29 29 Additional paid-in capital (4,731) ~~net~~(4,731) ofAccumulated ~~tax~~deficit ~~benefit~~(120,075) of(107,964) $7Subscriptions receivable (2,~~136~~974) --(2,974) Accumulated other comprehensive loss (1115,~~160~~234) (16,035) ---------- ---------- ~~Loss~~Total ~~before~~shareholders' ~~cumulative~~deficit ~~effect of change in accounting principle~~ (6142,~~747~~985) (31131,~~438~~675) ~~Cumulative effect of change in accounting principle (355)~~ -- --------- ---------- ~~Net~~Total ~~loss~~liabilities $and shareholders' equity (~~7,102~~deficit) $ ~~(31~~348,~~438)~~637 $ 349,323 ========== ==========

See accompanying notes to condensed consolidated financial statements. 2 4 MAXXIM MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands) (Unaudited)

~~Fiscal~~Three ~~Quarter~~Months Ended Six Months Ended ---------------------------- ~~January 28, January 30, 2001 2000~~ ----------- ----------------- ~~Cash~~April ~~flows~~29, ~~from~~April ~~operating~~30, ~~activities:~~April ~~Net loss $(7~~29,~~102)~~ $April ~~(31~~30,~~438)~~ ~~Adjustment~~2001 to2000 ~~reconcile~~2001 ~~net~~2000 ~~income~~---------- to---------- ~~net~~---------- ~~cash~~---------- ~~provided~~Net bysales ~~operating~~$ ~~activities:~~134,299 ~~Loss~~$ on130,760 ~~fair~~$ ~~value~~257,797 of$ ~~investment in derivative and hedging securities 1~~253,~~645~~588 --Cost ~~Loss on sale~~ of ~~investment~~sales in102,183 ~~derivative~~101,221 ~~securities~~196,003 ~~151~~194,063 -- ~~Cumulative effect of change in accounting principle 355~~ -------- ~~Debt tender and recapitalization expenses~~ ---------- ~~37,029 Deferred income tax expense~~ ---------- ~~74 Write~~-~~off~~--------- ofGross ~~debt~~profit ~~offering~~32,116 ~~costs~~29,539 --61,794 759,~~100~~525 ~~Amortization~~Selling, ofgeneral ~~financing fees~~ and ~~accretion~~administrative ofexpenses ~~debt discount 3~~23,~~748~~234 225,~~921~~265 ~~Depreciation and amortization 4~~44,~~045~~813 547,~~560~~794 ~~Change~~Restructure incharges ~~operating~~and ~~assets~~transition ~~and~~expenses ~~liabilities~~-- ~~(5,945)~~833 ~~(18~~-- 1,~~717)~~673 ---------- ---------- ~~Net cash (used in) provided by operating activities (3,103) 2,529~~ ------- --- ------ ~~Cash flows from investing activities: Proceeds from sale of investment in derivative securities 250~~ -- ~~Proceeds from sale of Circon~~ -- ~~228,000~~Income ~~Proceeds~~ from ~~sale~~operations of8,882 ~~investment~~3,441 ~~securities~~16,981 --10,058 ~~445~~Interest ~~Payment~~expense, ~~received~~net on(13,055) ~~notes~~(12,146) --(27,203) ~~869 Purchase of property~~(23,398) ~~equipment~~Other ~~and~~income ~~other assets~~(expense), net of(836) ~~asset~~(2,100) ~~acquisitions~~(1,534) ~~and~~(2,342) ~~business~~Recapitalization ~~combinations~~expenses -- (~~331~~201) -- (418,~~460~~898) ---------- ---------- ~~Net cash (used in) provided by investing activities (81) 224,854~~ ---------- ---------- ~~Cash~~Loss ~~flows~~ from ~~financing~~continuing ~~activities:~~operations ~~Net~~before ~~proceeds~~income ~~from~~taxes ~~the~~(5,009) ~~issuance~~(11,006) of(11,756) ~~senior~~(34,580) ~~subordinated~~Income ~~discount~~tax ~~notes~~benefit -- ~~110~~(3,~~004~~719) ~~Repurchase of 101/2% senior subordinated notes~~ -- (996,~~995~~928) ~~Increase~~---------- in---------- ~~long~~-~~term~~--------- ~~borrowings~~ ---------- ~~260,000~~Loss ~~Repayment~~from ofcontinuing ~~long-term~~operations ~~borrowings~~(5,009) (~~430~~7,287) (~~254~~11,~~000~~756) ~~Net~~(27,652) ~~proceeds~~Income from ~~the~~discontinued ~~issuance~~operations, net of ~~senior~~tax ~~discount~~of ~~notes~~$56 -- ~~50,000~~-- ~~Net~~-- ~~borrowings~~87 ~~(payments)~~---------- on---------- ~~revolving~~---------- ~~line of credit 1,500~~ ---------- ~~Payments~~Loss onbefore ~~capital~~extraordinary ~~leases~~item ~~and other long-term obligations~~ (~~150~~5,009) (~~525~~7,287) ~~Recapitalization of Maxxim --~~ (~~232~~11,~~361~~756) ~~Debt tender and recapitalization expenses --~~ (3727,~~029~~565) ~~Payment~~Extraordinary ofitem ~~debt offering costs~~ -- ~~(20,616)~~loss ~~(Decrease)~~related ~~increase~~to inearly ~~bank~~retirement ~~overdraft~~of 1debt,~~837~~ ~~(1,243)~~net ~~Other,~~of ~~net~~tax ~~(27)~~benefit ~~(537)~~of $7,136 -- --~~---~~ --~~-------~~ ~~Net cash provided by~~ (~~used in) financing activities 2~~11,~~730 (226,302~~160) ---------- ---------- ~~Effect of foreign currency translation adjustment 100 (94)~~ ---------- ---------- ~~Net~~Loss ~~(decrease)~~before ~~increase~~cumulative effect of change in ~~cash~~accounting ~~and~~principle ~~cash~~(5,009) ~~equivalents~~(7,287) (~~354~~11,756) ~~987~~(38,725) ~~Cash~~Cumulative ~~and~~effect ~~cash~~of ~~equivalents~~change atin ~~beginning~~accounting ofprinciple ~~period~~-- ~~1,287~~-- ~~4,040~~(355) -- ---------- ---------- ~~Cash~~---------- ~~and~~---------- ~~cash~~Net ~~equivalents~~loss at$ ~~end~~(5,009) of$ ~~period~~(7,287) $ ~~933~~(12,111) $ 5(38,~~027~~725) ========== ========== ~~Supplemental~~========== cash flow disclosures: Interest paid during the period $ 7,760 $ 10,671 Income taxes paid during the period -- 1,365 Noncash investing and financing activities Net unrealized (loss) gain on investment $ (385) $ 861==========

See accompanying notes to condensed consolidated financial statements. 3 5 MAXXIM MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED, IN THOUSANDS)

~~JANUARY~~Six ~~28,~~Months ~~OCTOBER~~Ended --------------------------- April 29, April 30, 2001 2000 ---------- ---------- Cash flows from operating activities: Net loss $ (12,111) $ (38,725) Adjustment to reconcile net loss to net cash provided by operating activities: Loss in fair value of investment in derivative and hedging securities 907 -- Loss on sale of investment in derivative securities 151 -- Cumulative effect of change in accounting principle 355 -- Debt tender and recapitalization expenses -- 37,230 Deferred income tax benefit -- (2,373) Write-off of debt offering costs -- 7,100 Amortization of financing fees and accretion of debt discount 7,408 6,351 Depreciation and amortization 8,048 11,449 Change in operating assets and liabilities (~~UNAUDITED~~3,609) (IN14,106) ~~THOUSANDS~~---------- ---------- Net cash provided by operating activities 1,149 6,926 ---------- ---------- Cash flows from investing activities: Proceeds from sale of investment in derivative securities 250 -- Proceeds from sale of Circon -- 228,000 Proceeds from sale of investment securities -- 884 Payment received on notes -- 1,036 Payment for contract rights -- (2,250) ~~Raw~~Purchase ~~materials~~of $property, 35equipment and other assets,~~865~~ ~~$32~~net of asset acquisitions and business combinations (1,~~667~~957) ~~Work~~(4,894) ---------- ---------- Net cash (used in) ~~progress~~provided 9by investing activities (1,~~476~~707) 9222,~~301~~776 ~~Finished~~---------- ~~goods~~---------- 34Cash flows from financing activities: Net proceeds from the issuance of senior subordinated discount notes -- 110,~~308~~004 41Repurchase of 10 1/2% senior subordinated notes -- (99,~~063~~995) ~~Allowance~~Increase ~~for~~in ~~excess~~long-term borrowings -- 260,000 Repayment of long-term borrowings (430) (254,000) Net proceeds from the issuance of senior discount notes -- 50,000 Net borrowings (payments) on revolving line of credit 7,000 -- Payments on capital leases and ~~obsolete~~other long-term obligations (13498) (676) Recapitalization of Maxxim -- (232,~~454~~361) Debt tender and recapitalization expenses -- (1637,~~118~~230) Payment of debt offering costs -- (21,330) (Decrease) increase in bank overdraft (4,054) 363 Other, net (339) (390) ---------- ---------- Net cash provided by (used in) financing activities 1,679 (225,615) ---------- ---------- Effect of foreign currency translation adjustment 65 (136) ---------- ---------- Net increase in cash and cash equivalents 1,186 3,951 Cash and cash equivalents at beginning of period 1,287 4,040 ---------- ---------- Cash and cash equivalents at end of period $ 662,~~195~~473 $66 7,~~913~~991 ========== ========== Supplemental cash flow disclosures: Interest paid during the period $ 18,584 $ 13,219 Income taxes paid during the period -- 1,365 Noncash investing and financing activities Net unrealized (loss) gain on investment $ (322) $ 696

See accompanying notes to condensed consolidated financial statements. 4 6 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) NOTE 1 - BASIS OF PRESENTATION On November 12, 1999, Maxxim Medical, Inc. ("Maxxim" or the "Company") was recapitalized in a going private transaction. Current financial information includes the accounts of Maxxim, Maxxim Medical Group, Inc. ("Maxxim Group") and Maxxim Group's wholly owned subsidiaries. Effective November 1, 2000, we announced a 5.2 for 1 stock split in the form of stock dividend of 4.2 shares of common stock on each share of common stock issued and outstanding on such effective date. These financial statements have been adjusted to reflect this stock split. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles have been omitted. The accompanying unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements should be read in conjunction with Maxxim's annual audited financial statements for the fiscal year ended October 29, 2000, included in its Annual Report on Form 10-K as filed with the Securities and Exchange Commission. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES FISCAL QUARTER The second quarter of fiscal 2001 ended on April 29th compared to the fiscal 2000 second quarter end date of April 30th. INVENTORIES Inventory includes the following as of:

~~FISCAL~~APRIL ~~QUARTER ENDED JANUARY 28~~29, ~~JANUARY~~OCTOBER 3029, 2001 2000 ----------- ----------- (UNAUDITED) (IN THOUSANDS) ~~Net~~Raw ~~loss~~materials .......................... $(7 46,~~102)~~416 $~~(31~~ 32,~~438)~~667 ~~Foreign~~Work ~~currency~~in ~~translation~~progress ~~adjustments~~....................... 111,~~629~~037 (19,~~546)~~301 ~~Net~~Finished ~~unrealized~~goods ~~gains~~......................... ~~(losses)~~34,784 on41,063 ~~available~~Allowance for ~~sale~~excess ~~securities~~and obsolete ...... (~~385~~10,583) ~~861~~(16,118) -------- -------- ~~Total comprehensive loss~~ $(5 81,~~858)~~654 $~~(32~~ 66,~~123)~~913 ======== ========

GOODWILL Goodwill represents the excess of the aggregate price paid by Maxxim in business combinations accounted for as purchases over the fair market value of the tangible and identifiable intangible net assets acquired. Goodwill from the Company's previous acquisitions is approximately $157,608,000 of which approximately $108,979,000 remains unamortized as of April 29, 2001. Amortization periods for goodwill range from 5 to 40 years. The Company evaluates its goodwill for impairment on comparison of carrying value against undiscounted future pre-tax cashflows. If an impairment is identified, we adjust the asset's carrying amounts to the value of future discounted cashflows. 5 7 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) INCOME TAXES Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. COMPREHENSIVE INCOME (LOSS) Comprehensive income (loss) includes all changes in a company's equity including, among other things, unrealized holding gains and losses on available-for-sale securities and foreign currency translation adjustments. Total comprehensive income is as follows:

~~JANUARY~~THREE ~~28,~~MONTHS ~~2001~~ENDED ~~OCTOBER~~APRIL 29, APRIL 30, 2001 2000 ---------~~---------------------~~ ---------~~-----------------------~~ ~~CARRYING~~(IN ~~AMOUNT~~THOUSANDS) ~~FAIR~~Net ~~VALUE~~loss ~~CARRYING~~............................................................ ~~AMOUNT~~$ ~~FAIR~~(5,009) ~~VALUE~~$ (7,287) Foreign currency translation adjustments ............................ (506) 1,741 Net unrealized gains (losses) on available for sale securities ...... 63 (165) --------~~-------~~ ---------- Total comprehensive loss ............................................ $ (5,452) $ (5,711) ======== ======== SIX MONTHS ENDED APRIL 29, APRIL 30, 2001 2000 ---------~~------~~ ---------- (~~UNAUDITED~~IN THOUSANDS) ~~Interest~~Net ~~rate~~loss ~~cap~~............................................................. $ 44(12,~~555~~111) $ 44(38,~~555~~725) $Foreign ~~576,000~~currency $translation ~~220,786~~adjustments ~~Swap~~............................. ~~agreement~~1,123 ~~paying~~195 ~~fixed~~Net ~~136,001~~unrealized ~~136,001~~gains ~~2,006,609~~(losses) ~~2,006,609~~on ~~Long-term~~available ~~debt~~for ~~(including~~sale ~~current~~securities ~~maturities)~~....... (~~382,430~~322) ~~(382,430)~~696 -------- -------- Total comprehensive loss ............................................. $(~~379~~11,~~017~~310) $(~~379~~37,~~017~~834) ======== ========

NOTE 3 - BUSINESS COMBINATIONS, SIGNIFICANT ASSET ACQUISITIONS, DISPOSITIONS AND DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS On November 12, 1999, in connection with the recapitalization, Maxxim sold all of the common stock of Circon Corporation, a wholly owned subsidiary of the Company, to Circon Holdings Corporation ("Circon Holdings"), a newly formed Delaware corporation. Income of $87,000 from these discontinued operations was recorded in the quarter ended January 30, 2000. 6 8 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) NOTE 4 - DEBT The following summarizes the Company's long-term debt as of:

~~JANUARY~~APRIL 2829, 2001 ~~----------------------------------------------------------------------------------~~OCTOBER GUARANTOR NON-GUARANTOR MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES TOTAL GUARANTOR TOTAL ------------ ------------- ------------ --------- ------------ ASSETS Current assets: Cash and cash equivalents $ 323 $ 610 $ 933 $ -- $ 933 Accounts receivable29, ~~net~~2000 ~~43,954 9,642 53,596~~ -- ~~53,596 Inventory, net 54,229 11,966 66,195~~ -- ~~66,195 Other receivables 10,746~~ -- ~~10,746 4,278 15,024 Prepaid expenses and other 3,200 647 3,847~~ -- ~~3,847 Assets held for sale 18,388~~ -- ~~18,388~~ -- ~~18,388~~ --~~-------~~ -------- --------- ~~--------- --------- Total current assets 130,840 22,865 153,705 4,278 157,983 Property and equipment 52,730 53,543 106,273 -- 106,273 Less: accumulated depreciation~~ (~~29,256~~UNAUDITED) (~~21,532)~~In ~~(50,788~~thousands) --Industrial ~~(50,788)~~revenue ~~---------~~bonds ~~--------~~............... --------- --------- --------- 23,474 32,011 55,485 -- 55,485 Goodwill and other intangibles, net 109,072 958 110,030 -- 110,030 Other assets, net 23,067 627 23,694 2,209 25,903 --------- -------- --------- --------- --------- Total assets $ ~~286~~1,~~453~~940 $ 562,~~461~~370 $Revolving ~~342,914~~line ~~$ 6,487 $ 349,401 ========= ======== ========= ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current liabilities: Current maturities~~ of ~~long-term~~credit ~~debt~~............... ~~$ 10~~7,~~708~~000 $ -- $Term ~~10,708~~loans $under --credit $facility ~~10,708~~....... ~~Current maturities of capital leases and other long term obligations 679 -- 679 -- 679 Accounts payable 42~~208,~~537~~500 6208,~~636~~500 ~~49,173~~ -- ~~49,173 Accrued liabilities 48,129 2,363 50,492~~ -- ~~50,492~~ ------~~---~~ -------- --~~-------~~ ~~--------- ---------~~ Total ~~current~~long ~~liabilities 102,053 8,999 111,052 -- 111,052 Intercompany (receivable) payable (33,557) 33,557 -- -- -- Long-~~term debt, ~~net~~................ ~~of current maturities 201~~217,~~232~~440 ~~-- 201~~210,~~232~~870 --Less ~~201,232 Senior subordinated discount notes 110,976~~ -- ~~110,976~~Current ~~-- 110,976 Senior discount notes -- -- -- 55,648 55,648 10 1/2% Senior subordinated notes 5 -- 5 -- 5 Capital leases and other long term obligations, net of current~~ maturities ~~3,611~~.............. -- 3,611 -- 3,611 --------- -------- --------- --------- --------- Total liabilities 384,320 42,556 426,876 55,648 482,524 Shares with put rights -- -- -- 4,410 4,410 Commitments and contingencies Shareholders' deficit: Preferred Stock -- -- -- -- -- Common Stock -- -- -- 29 29 Additional paid-in capital -- -- -- (410,~~731~~708) (410,~~731~~688) ~~Retained earnings~~ -- -- -- ~~(115,066) (115,066) Subscriptions receivable~~ -- -- -- ~~(2,974) (2,974) Accumulated other comprehensive loss~~ -- -- -- ~~(14,791) (14,791)~~ --~~-------~~ -------- --------- --------- --------- Total shareholders' deficit -- -- -- (137,533) (137,533) (Investment in) / net equity of guarantor subsidiaries (83,962) -- (83,962) 83,962 -- (Investment in) / net equity of Non-guarantor subsidiaries (13,905) 13,905 -- -- -- --------- -------- --------- --------- --------- Total liabilities and shareholders' equity (deficit) $ ~~286~~206,~~453~~732 $ 56200,~~461~~182 ~~$ 342,914 $ 6,487 $ 349,401~~ ========= =~~=======~~ ========= =~~======== =========~~

NOTE 5 - FINANCIAL INSTRUMENTS Statement of Financial Accounting Standards No. 133, "Accounting for Derivative Instruments and Hedging Activities" (SFAS No. 133), was issued by the Financial Accounting Standards Board in June 1998. SFAS No. 133 standardizes the accounting for derivative instruments, including certain derivative instruments embedded in other contracts. Under the standard, entities are required to carry all derivative instruments in the statement of financial position at fair value. SFAS No. 133 is effective for all fiscal quarters of all fiscal years beginning after June 15, 2000. Maxxim has adopted SFAS No. 133 and recorded a cumulative change in accounting method of $355,000 in the first quarter of fiscal 2001. In January 1999, the Company entered into swap agreements with three banks participating in the Company's Third Credit Agreement. The total notional value of the swaps are $125,000,000. In the first quarter of fiscal 2001, the Company terminated one of the swap agreements, with a notional value of $25,000,000, for a payment of $250,000. The agreement fixed a portion of the Company's non-indexed part of the interest rate at 5.08% and 5.02%, so long as LIBOR does not exceed 6.75%. The Company used the interest rate swap to manage the interest risk associated with its borrowings and to manage the Company's allocation of fixed and variable rate debt associated with the credit facility in existence prior to the recapitalization. This swap agreement was continued by the Company subsequent to termination of the Company's previous credit facility . The swap was redesignated as a speculative position for accounting purposes and has been recorded at its market value in the financial statements. The Company includes gains and losses associated with recording this instrument at fair value as a component of interest expense. Pursuant to the Credit Facility, Maxxim Group and the Chase Manhattan Bank entered into a hedging arrangement to cap Maxxim Group's floating interest rate at 8.0% on an agreed upon notional principal amount of $130,000,000, in April 2000. The Company has designated this instrument as a cash flow hedge and has recorded the instrument at fair value in its financial statements as of October 30, 2000. Accordingly, the Company recorded a $355,000 transition entry to record the instrument at fair value upon the adoption of SFAS No. 133. Subsequent adjustments to the fair value of this instrument have been recorded as a component of interest expense. The estimated fair value of cash and cash equivalents, accounts receivable, and accounts payable, approximate their carrying amount. The estimated fair values and carrying amounts of long-term borrowings and the interest rate swap and cap were as follows:

APRIL 29, 2001 OCTOBER 29, 2000 ------------------------------- -------------------------------~~---------------------~~ ~~GUARANTOR~~CARRYING ~~NON-GUARANTOR~~AMOUNT ~~MAXXIM~~FAIR ~~GROUP~~VALUE ~~PARENT~~CARRYING ~~CONSOLIDATED~~AMOUNT ~~SUBSIDIARIES~~FAIR ~~SUBSIDIARIES~~VALUE ~~TOTAL GUARANTOR TOTAL~~ ------------ ---~~----------~~ ------------ --------- ------~~------~~ ~~ASSETS Current assets: Cash and cash equivalents $ 171 $ 1,116 $ 1,287 $~~ -- ~~$ 1,287 Accounts receivable, net 38,454 7,802 46,256~~ -- ~~46,256 Inventory, net 55,697 11,216 66,913~~ -- ~~66,913 Other receivables 10,746~~ -- ~~10,746 4,278 15,024 Prepaid expenses and other 4,859 1,047 5,906~~ -- 5,906 Assets to be held for sale 18,388 -- 18,388 -- 18,388 --------- -------- --------- --------- --------- Total current assets 128,315 21,181 149,496 4,278 153,774 Property and equipment 52,699 51,253 103,952 -- 103,952 Less: accumulated depreciation (~~27,971~~UNAUDITED) (~~19,235)~~In ~~(47,206~~thousands) --Interest ~~(47,206)~~rate ~~---------~~cap ~~--------~~............... --------- --------- --------- 24,728 32,018 56,746 -- 56,746 Goodwill, net 110,067 902 110,969 -- 110,969 Other assets, net 24,983 605 25,588 2,246 27,834 --------- -------- --------- --------- --------- Total assets $ ~~288,093~~22 $ ~~54,706~~22 $ ~~342,799~~576 $ ~~6,524~~221 $Swap ~~349~~agreement,~~323~~ ~~=========~~paying ~~========~~fixed ~~=========~~.... ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current maturities of long-term debt $ 10,688 $ -- $ 10,688 $ -- $ 10,688 Current maturities of capital leases and other obligations 712 -- 712 -- 712 Accounts payable 41,676 5,829 47,505 -- 47,505 Accrued liabilities 48,243 1,823 50,066 -- 50,066 --------- -------- --------- --------- --------- Total current liabilities 101,319 7,652 108,971 -- 108,971 Intercompany (~~receivable~~748) ~~payable~~ (~~35,221~~748) 352,~~221~~007 --2,007 ~~-- --~~ Long-term debt, ~~net~~(including of current maturities 200,182 -- 200,182 -- 200,182 Senior subordinated discount notes 110,123 -- 110,123 -- 110,123 Senior discount notes -- -- -- 53,579 53,579 10 1/2% Senior subordinated notes 5 -- 5 -- 5 Capital lease and other obligations, net of current maturities 3,728 -- 3,728 -- 3,728 --------- -------- --------- --------- --------- Total liabilities 380,136 42,873 423,009 53,579 476,588 Shares with put rights Commitments and contingencies -- -- -- 4,410 4,410 Shareholders' equity: Preferred Stock -- -- -- -- -- Common Stock -- -- -- 29 29 Additional paid-in capital -- -- -- (4,731) ~~(4,731)~~......... ~~Accumulated deficit -- -- --~~ (~~107~~390,~~964~~957) (~~107~~390,~~964~~957) ~~Subscriptions receivable -- -- --~~ (2379,~~974~~017) (2379,~~974~~017) Accumulated other comprehensive loss -- -- -- (16,035) (16,035) --------- -------- --------- --------- --------- Total shareholders' equity -- -- -- (131,675) (131,675) (Investment in) / net equity of Guarantor subsidiaries (80,210) -- (80,210) 80,210 -- (Investment in) / net equity of Non-guarantor subsidiaries (11,833) 11,833 -- -- -- --------- -------- --------- --------- --------- Total liabilities and shareholders' equity $ 288,093 $ 54,706 $ 342,799 $ 6,524 $ 349,323 ========= ======== ========= ========= =========

7 9 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) Fair values for the Company's 10 1/2% Senior Subordinated Notes were based upon the redemption value paid in connection with the recapitalization. Fair values for the Company's other debts were determined from quoted market prices or estimated discounted cash flows. NOTE 6 - OTHER ASSETS Other assets, net of accumulated amortization, include the following as of:

~~FISCAL~~APRIL ~~QUARTER~~29, ~~ENDED~~OCTOBER ~~JANUARY 28~~29, 2001 ~~-----------------------------------------------------------------------------------------------~~2000 ~~GUARANTOR NON~~-~~GUARANTOR ELIMINATING MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES ENTRIES TOTAL GUARANTOR TOTAL~~ ---------~~---~~ ------------- ~~-----------~~(UNAUDITED) ~~------------~~(IN ~~--------~~THOUSANDS) ~~------------~~Patents ~~Net~~...................... ~~sales~~ $ ~~112~~3,~~025~~801 $ 164,~~844~~118 $Debt ~~5,371~~offering $costs ~~123,498~~.......... ~~$ -- $ 123~~19,~~498~~011 Cost of sales 85,757 13,434 5,371 93,820 -- 93,820 --------- -------- -------- --------- -------- --------- Gross profit 26,268 3,410 -- 29,678 -- 29,678 --------- -------- -------- --------- -------- --------- Selling, general and administrative 18,926 2,653 -- 21,~~579~~105 Non--compete ~~21,579~~agreements ~~---------~~....... ~~--------~~563 ~~--------~~596 ~~---------~~Notes ~~--------~~receivable ~~---------~~............. ~~Income~~159 ~~from~~338 ~~operations 7,342 757 -- 8,099 -- 8,099 Interest (expense), net (11,524) (518) -- (12,042) (2,106) (14,148)~~ Other ~~income/(expense),~~........................ ~~net (506) (192) -- (698) -- (698) --------- -------- -------- --------- -------- --------- Income (loss) before cumulative effect of change in accounting (4,688) 47 -- (4,641) (~~2,~~106)~~101 (61,~~747)~~677 ~~Cumulative effect of change in accounting principle (355)~~ -- -- ~~(355)~~ -- ~~(355)~~ ----~~-----~~ -------- --~~------~~ ~~--------- -------- --------- Net income (loss)~~ $ (525,~~043)~~635 $ ~~47 $ -- $ (4~~27,~~996)~~834 ~~$ (2,106) $ (7,012)~~ ========= =~~=======~~ ======== ==~~======= ======== =========~~

NOTE 7 - BUSINESS SEGMENTS, GEOGRAPHIC AREAS AND MAJOR CUSTOMERS The Company's business is organized, managed and internally reported as a single segment comprised of medical products used in surgical and other medical procedures. The Company believes its various product lines have similar economic, operating and other related characteristics. Information in the table below is presented on the basis Maxxim uses to manage its business. Export sales are reported within the geographic areas where the final sales to customers are made.

~~FISCAL~~THREE ~~QUARTER~~MONTHS ENDED ~~JANUARY~~APRIL 3029, ~~2000~~2001 ~~-----------------------------------------------------------------------------------------------~~APRIL ~~GUARANTOR~~30, ~~NON-GUARANTOR~~2000 ~~ELIMINATING MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES ENTRIES TOTAL GUARANTOR TOTAL~~ ------------ --~~-----------~~ ----------- ---~~---------~~ ~~-------- ------------ Net sales $ 109~~(UNAUDITED,~~095~~ $IN ~~20,786 $ (7,053~~THOUSANDS) $United ~~122,828~~States $........... -- $ ~~122~~117,~~828~~650 ~~Cost of sales 79~~$112,~~612~~799 ~~17,338~~Europe ~~(7,053)~~.................. 8910,~~897~~736 ~~-- 89~~11,~~897~~269 ~~---------~~Rest ~~--------~~of ~~--------~~World ~~---------~~........... ~~-------- --------- Gross profit 29~~5,~~483~~913 36,~~448~~692 -- ~~32,931~~ -- ~~32,931~~ ----~~-----~~ -------- ~~--------~~Total ~~---------~~Company ~~--------~~........... ~~--------- Selling~~$134,299 ~~general and Administrative 18~~$130,~~880~~760 ~~3,649~~======== --======== ~~22,529~~SIX --MONTHS ~~22,529~~ENDED ~~Restructure~~APRIL ~~and transition Expenses 3~~29,~~785~~ --2001 --APRIL 330,~~785~~ --2000 ~~3,785~~ --------- -----~~---~~ -------- ------~~---~~ ~~-------- --------- 22,665 3,649 -- 26,314 -- 26,314 --------- -------- -------- --------- -------- --------- Income~~ (~~loss) from operations 6~~UNAUDITED,~~818~~ ~~(201)~~IN ~~-- 6,617 -- 6,617 Interest (expense~~THOUSANDS), ~~net~~United ~~(9,024)~~States ~~(593)~~...... ~~-- (9~~$225,~~617)~~289 (1$217,~~635)~~681 ~~(11,252)~~Europe ~~Other~~............. income/(expense), net (265) 23 -- (242) -- (242) Recapitalization expenses (18,697) -- -- (18,697) -- (18,697) --------- -------- -------- --------- -------- --------- Loss before income taxes (21,168) (771) -- (21,939) (1,635) (23,574) Income tax benefit (2,287) (284) -- (2,571) (638) (3,209) --------- -------- -------- --------- -------- --------- Loss from continuing Operations (18,881) (487) -- (19,368) (997) (20,~~365)~~805 ~~Income from discontinued operations~~22,581 ~~net~~Rest ~~87 -- -- 87 -- 87 --------- -------- -------- --------- -------- --------- Loss before extraordinary item (18,794) (487) -- (19,281) (997) (20,278) Extraordinary item - loss on early retirement~~ of ~~debt,~~World ~~net~~...... (811,~~084)~~703 ~~-- -- (8~~13,~~084)~~326 ~~(11,160)~~ --------- -------- ~~--------~~Total ~~---------~~Company ~~--------~~...... ~~--------- Net loss~~ $ ~~(26~~257,~~878)~~797 $ ~~(487) $ -- $ (27~~253,~~365)~~588 ~~$ (4,073) $ (31,438)~~ ========= ======== ~~======== ========= ======== =========~~

Export sales to rest of world are primarily sales to Canada, South America and the Pacific Rim. There were no significant investments in long-lived assets located outside the United States at April 29, 2001 and October 29, 2000. The Company distributes primarily through major distributors in the United States. Those distributors typically serve under a purchase order or supply agreement between the end-user and the Company. Sales through Owens & Minor, Inc., and General Medical Corp., our largest distributors, were 34.9% and 9.2% of our net sales in the United States, respectively, for the six months ended April 29, 2001, and 26.8% and 10.8% of our net sales, respectively, for the six months ended April 30, 2000. For the six months ended April 29, 2001, no other single distributor accounted for more than 10% of our total net sales in the United States. 8 10 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) NOTE 8 - RELATED PARTY TRANSACTIONS LOANS TO RELATED PARTIES In connection with the recapitalization, the continuing shareholders received loans in the aggregate amount of $2,580,000 for the purchase of Maxxim common stock which are reflected as subscriptions receivable in the accompanying balance sheet. Also in connection with the recapitalization, the continuing shareholders received loans from Maxxim totaling $1,559,000 in an amount sufficient to cover the taxes due on the cash received from the conversion of the 2,056,413 shares used to purchase Circon Holdings shares. Under the terms of the Company's former Chief Executive Officer's ("CEO") employment agreement, the former CEO could borrow up to an aggregate of $500,000 for the principal purpose of payment of federal income tax payments associated with the exercise of stock options to purchase shares of the Company's common stock. Each loan was non-interest bearing, unsecured and repayable in ten equal annual installments on the third through the twelfth anniversaries of the dates of such loans. The total amount outstanding under this loan agreement was $500,000 at April 29, 2001. The former CEO is delinquent in payment of his fiscal 2000 repayment obligation under the loans. In conjunction with the relocation of the Company's former Chief Operations Officer ("COO") from Houston, Texas to the Company's corporate headquarters in Clearwater, Florida, the former COO received a loan in the amount of $320,000. This loan is non-interest bearing, unsecured and repayable upon the earlier of the sale of his prior residence or December 31, 2000. The former COO is delinquent in payment of his obligation under this loan. On May 31, 2000, Maxxim executed a $270,000 promissory note to its former Corporate Controller. This loan is non-interest bearing, unsecured and repayable on June 3, 2006. NOTE 9 - FINANCIAL INFORMATION REGARDING GUARANTOR SUBSIDIARIES Consolidating financial information regarding the Company, guarantor subsidiaries and non-guarantor subsidiaries as of April 29, 2001 and October 29, 2000 and for each of the fiscal quarters ended April 29, 2001 and April 30, 2000 is presented below for purposes of complying with the reporting requirements of the guarantor subsidiaries. Separate financial statements and other disclosures concerning each guarantor subsidiary have not been presented because management has determined that such information is not material to investors. The guarantor subsidiaries are wholly-owned subsidiaries of Maxxim that have fully and unconditionally guaranteed the Senior Subordinated Discount Notes due 2009 issued in connection with the recapitalization. 9 11 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONDENSED CONSOLIDATED BALANCE SHEET APRIL 29, 2001

~~FISCAL~~APRIL ~~QUARTER ENDED JANUARY 28~~29, 2001 ------------------------------------------------------------------------------------ GUARANTOR NON-GUARANTOR MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES TOTAL GUARANTOR TOTAL ------------ ------------- ------------ ---------- ------------ ~~Cash~~ASSETS ~~flows~~Current ~~from operating activities~~assets: ~~Net~~Cash ~~income~~and ~~(loss)~~cash ~~$(5,043)~~equivalents $ 47648 $(4 1,~~996)~~825 $( 2,~~106)~~473 $~~(7,102)~~ ~~Adjustment~~-- to$ ~~reconcile~~2,473 ~~net~~Accounts ~~income~~receivable, to net ~~cash~~42,669 ~~provided~~9,518 by52,187 ~~operating~~-- ~~activities:~~52,187 ~~Loss~~Inventory, onnet ~~fair~~70,313 ~~value~~11,341 of81,654 ~~investment~~-- in81,654 ~~Derivative~~Other ~~and~~receivables ~~hedging securities 1~~2,~~645~~561 -- 12,~~645~~561 -- 12,~~645~~561 ~~Loss~~Prepaid onexpenses ~~sale~~and ofother ~~derivative~~3,014 ~~securities~~340 ~~151~~3,354 -- ~~151~~3,354 --Assets ~~151~~held ~~Cumulative~~for ~~effect~~sale of18,388 ~~accounting~~-- ~~change~~18,388 ~~355~~ -- ~~355~~18,388 ---------- ~~355~~---------- ~~Amortization~~---------- of---------- ~~financing~~---------- ~~fees~~Total ~~and~~current ~~accretion~~assets ~~of debt discount 1~~137,~~642~~593 ~~-- 1~~23,~~642~~024 2160,~~106~~617 3160,~~748~~617 ~~Depreciation~~Property and ~~amortization~~equipment 253,~~661~~148 153,~~384~~212 4106,~~045~~360 -- 4106,~~045~~360 ~~Change~~Less: inaccumulated ~~operating~~depreciation ~~assets and liabilities~~ (430,~~239~~564) (122,~~706~~390) (552,~~945~~954) -- (552,~~945~~954) ---------- ---------- ---------- ---------- ---------- ~~Net~~22,584 ~~cash~~30,822 ~~(used~~53,406 ~~in)~~-- ~~provided~~53,406 byGoodwill ~~operating~~and ~~activities~~other (2intangibles,~~828)~~ ~~(275)~~net (3108,~~103)~~100 879 108,979 -- (3108,~~103)~~979 Other assets, net 22,891 572 23,463 2,172 25,635 ---------- ---------- ---------- ---------- ---------- ~~Cash~~Total ~~flows~~assets ~~from~~$ ~~investing~~291,168 ~~activities:~~$ ~~Proceeds~~55,297 ~~from~~$ ~~sale~~346,465 of$ ~~investment~~2,172 In$ ~~derivative~~348,637 ~~securities~~========== ~~250~~========== --========== ~~250~~========== --========== ~~250~~LIABILITIES ~~Purchase~~AND ofSHAREHOLDERS' ~~property,~~EQUITY ~~equipment~~(DEFICIT) ~~and~~Current ~~other~~liabilities: ~~assets,~~Current ~~net~~maturities of ~~asset~~long-term ~~acquisitions~~debt ~~and~~$ ~~business~~10,708 ~~combinations~~$ ~~(67)~~-- ~~(264)~~$ ~~(331)~~10,708 $ -- ~~(331)~~$ ~~-------~~10,708 ~~-------~~Current ~~-------~~maturities of capital leases and other long term obligations 1,210 --~~-----~~ 1,210 --~~-----~~ ~~Net~~1,210 ~~cash~~Accounts ~~provided~~payable by42,760 ~~(used~~7,738 ~~in)~~50,498 ~~investing~~-- ~~activities~~50,498 ~~183~~Accrued ~~(264)~~liabilities ~~(81)~~41,049 3,961 45,010 -- ~~(81)~~45,010 ------- --- ---- ------- ---------- ---------- ---------- ~~Cash~~Total ~~flows~~current ~~from~~liabilities ~~financing~~95,727 ~~activities:~~11,699 ~~Repayment~~107,426 ~~on long~~-~~term~~- ~~borrowings~~107,426 Intercompany (~~430~~receivable) --payable (~~430~~31,300) 31,300 -- ~~(430)~~-- ~~Net~~-- ~~borrowings~~Long-term ondebt, ~~revolving~~net ~~line~~ of ~~credit~~current 1maturities 206,~~500~~732 -- 1206,~~500~~732 -- 1206,~~500~~732 ~~Payments~~Senior onsubordinated ~~capital~~discount ~~lease~~notes ~~and~~111,829 ~~other~~-- ~~long~~111,829 ~~term~~-- ~~obligations~~111,829 ~~(150)~~Senior discount notes -- ~~(150)~~-- -- ~~(150)~~57,740 ~~Decrease~~57,740 in10 ~~bank~~1/2% ~~overdraft~~Senior ~~1,837~~subordinated notes 5 -- ~~1,837~~5 -- ~~1,837~~5 ~~Other~~Capital leases and other long term obligations, net 40of ~~(67)~~current ~~(27)~~maturities 3,480 -- ~~(27)~~3,480 -- 3,480 ---------- ---------- ---------- ---------- ---------- ~~Net~~Total ~~cash~~liabilities ~~(used~~386,473 ~~in)~~42,999 ~~provided~~429,472 by57,740 ~~financing~~487,212 ~~activities~~Shares ~~2,797~~with ~~(67)~~put ~~2,730~~rights -- ~~2,730~~ -- -- 4,410 4,410 Commitments and contingencies Shareholders' deficit: Preferred Stock -- -- -- -- -- Common Stock -- -- -- 29 29 Additional paid-in capital -- -- -- (4,731) (4,731) Retained earnings -- -- -- (120,075) (120,075) Subscriptions receivable -- -- -- ~~Effect~~(2,974) of(2,974) ~~foreign~~Accumulated ~~currency~~other ~~translation~~comprehensive ~~adjustment~~loss -- ~~100~~-- ~~100~~ -- ~~100~~(15,234) (15,234) ---------- ---------- ---------- ---------- ---------- ~~Net~~Total ~~increase~~shareholders' deficit -- -- -- (~~decrease~~142,985) (142,985) (Investment in) ~~cash~~/ ~~and~~net ~~cash~~equity ~~Equivalents~~of ~~152~~guarantor ~~(506)~~subsidiaries (~~354~~83,007) -- (~~354~~83,007) ~~Cash~~83,007 ~~and~~-- ~~cash~~(Investment ~~equivalents~~in) at/ ~~beginning~~net equity of ~~period~~Non-guarantor ~~171~~subsidiaries 1(12,~~116~~298) 112,~~287~~298 -- ~~1,287~~-- -- ---------- ---------- ---------- ---------- ---------- ~~Cash~~Total liabilities and ~~cash~~shareholders' ~~equivalents~~equity at(deficit) ~~end of period~~ $ ~~323~~291,168 $ ~~610~~55,297 $ ~~933~~346,465 $ --2,172 $ ~~933~~348,637 ========== ========== ========== ========== ==========

10 12 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONSOLIDATED BALANCE SHEET OCTOBER 29, 2000 (IN THOUSANDS)

~~FISCAL~~OCTOBER ~~QUARTER ENDED JANUARY 30~~29, 2000 ------------------------------------------------------------------------------------ GUARANTOR NON-GUARANTOR MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES TOTAL GUARANTOR TOTAL ------------ ------------- ------------ ---------- ------------ ~~Cash~~ASSETS ~~flows~~Current ~~from~~assets: ~~operating~~Cash ~~activities:~~and ~~Net~~cash ~~loss~~equivalents $ ~~(26,878)~~171 $ ~~(487)~~1,116 $ ~~(27~~1,~~365)~~287 $ ~~(4,073)~~-- $ ~~(31~~1,~~438)~~287 ~~Adjustment~~Accounts toreceivable, ~~reconcile~~ net ~~income~~38,454 to7,802 ~~net~~46,256 ~~cash~~-- ~~provided~~46,256 byInventory, ~~operating~~net ~~activities:~~55,697 ~~Debt~~11,216 ~~tender~~66,913 ~~and~~-- ~~recapitalization~~66,913 ~~Expenses~~Other 37receivables 10,~~029~~746 -- 3710,~~029~~746 --4,278 3715,~~029~~024 ~~Deferred~~Prepaid ~~income~~expenses ~~tax~~and ~~(benefit)~~other ~~expense~~4,859 ~~(221)~~1,047 ~~295~~5,906 74 -- 745,906 ~~Write-off~~Assets ofto ~~debt~~be ~~offering~~held ~~costs~~for 2sale 18,~~057~~388 -- 218,~~057~~388 ~~5,043~~-- 718,~~100~~388 ~~Amortization~~---------- of---------- ~~financing~~---------- ~~fees~~---------- ~~and~~---------- ~~accretion~~Total ofcurrent ~~debt~~assets ~~discount~~128,315 121,~~285~~181 ~~-- 1~~149,~~285~~496 14,~~636~~278 2153,~~921~~774 ~~Depreciation~~Property and ~~amortization~~equipment 452,~~002~~699 151,~~558~~253 5103,~~560~~952 -- 5103,~~560~~952 ~~Change~~Less: inaccumulated ~~operating~~depreciation ~~assets and liabilities~~ (1127,~~739~~971) (~~24) (11~~19,~~763~~235) (647,~~954~~206) -- (1847,~~717~~206) ---------- ---------- ---------- ---------- ---------- ~~Net~~24,728 ~~cash~~32,018 ~~(used~~56,746 ~~in)~~-- ~~provided~~56,746 byGoodwill, ~~operating~~net ~~activities~~110,067 5902 110,~~535~~969 1-- 110,~~342~~969 6Other assets,~~877~~ (4net 24,~~348)~~983 605 25,588 2,~~529~~246 27,834 ---------- ---------- ---------- ---------- ---------- ~~Cash~~Total ~~flows~~assets ~~from~~$ ~~investing~~288,093 ~~activities:~~$ ~~Proceeds~~54,706 ~~from~~$ ~~sale of Circon 228~~342,~~000~~799 --$ ~~228~~6,~~000~~524 --$ ~~228~~349,~~000~~323 ~~Proceeds~~========== ~~from~~========== ~~sale~~========== of========== ~~investment~~========== ~~Securities~~LIABILITIES ~~445~~AND --SHAREHOLDERS' ~~445~~EQUITY --Current ~~445~~liabilities: ~~Payment~~Current ~~received~~maturities onof ~~notes~~long-term ~~869~~debt --$ ~~869~~10,688 $ -- ~~869~~$ ~~Purchase of property~~10,688 ~~equipment~~$ ~~and~~-- ~~other~~$ ~~assets~~10,688 ~~net~~Current maturities of ~~asset~~capital ~~acquisitions~~leases and ~~business~~other ~~combinations~~obligations ~~(3,456)~~712 ~~(1,004) (4,460)~~ -- ~~(4,460)~~712 --~~-------~~ ~~-------~~712 ~~---------~~Accounts ~~---------~~payable ~~---------~~41,676 ~~Net~~5,829 ~~cash~~47,505 ~~provided~~-- by47,505 ~~(used~~Accrued ~~in)~~liabilities ~~investing activities 225~~48,~~858~~243 (1,~~004)~~823 ~~224~~50,~~854~~066 -- ~~224~~50,~~854~~066 ---------- ---------- ---------- ---------- ---------- ~~Cash~~Total ~~flows~~current ~~from~~liabilities ~~financing~~101,319 ~~activities: Net proceeds from the issuance of senior subordinated discount notes 110~~7,~~004~~652 ~~-- 110~~108,~~004~~971 -- ~~110~~108,~~004~~971 ~~Repurchase~~Intercompany ~~of 10 1/2% senior subordinated notes~~ (~~99,995~~receivable) --payable (9935,~~995~~221) ~~-- (99~~35,~~995)~~221 ~~Increase in long~~-~~term~~- ~~borrowings 260,000~~ -- ~~260,000~~ -- ~~260,000 Repayment on long~~Long-term ~~borrowings -- -- -- (254~~debt,~~000)~~ ~~(254,000)~~net ~~Net proceeds from the issuance~~ of ~~senior~~current ~~discount~~maturities ~~notes~~200,182 -- --200,182 -- 50200,~~000~~182 ~~50,000~~Senior ~~Payments~~subordinated ondiscount ~~capital~~notes ~~lease~~110,123 ~~obligations (116)~~ -- ~~(116)~~110,123 -- ~~(116)~~110,123 ~~Payments~~Senior ondiscount ~~other~~notes ~~long term obligations (409)~~ -- ~~(409)~~ -- ~~(409) Recapitalization of Maxxim (443,170)~~ -- ~~(443~~53,~~170)~~579 ~~210~~53,~~809~~579 ~~(232,361)~~10 ~~Debt~~1/2% ~~tender~~Senior ~~and~~subordinated ~~recapitalization~~notes ~~Expenses~~5 ~~(37,029)~~ -- ~~(37,029)~~5 -- ~~(37,029)~~5 ~~Payment~~Capital oflease ~~debt~~and ~~offering~~other ~~costs (18~~obligations,~~155)~~ --net ~~(18,155)~~of ~~(2,461)~~current ~~(20,616)~~maturities ~~Decrease in bank overdraft (1~~3,~~243)~~728 -- (13,~~243)~~728 -- (13,~~243)~~728 ~~Other, net (244) (293) (537)~~ -- ~~(537)~~ --------- ---------- ---------- ---------- ---------- ~~Net~~Total ~~cash~~liabilities ~~(used~~380,136 ~~in)~~42,873 ~~provided~~423,009 by53,579 ~~financing activities (230~~476,~~357)~~588 ~~(293)~~Shares ~~(230,650)~~with ~~4,348~~put ~~(226,302)~~rights -- -- -- 4,410 4,410 Commitments and contingencies Shareholders' equity: Preferred Stock --- -- -- --- -- Common Stock -- -- -- 29 29 Additional paid-in capital -- -- -- (4,731) (4,731) Accumulated deficit --- -- --~~-----~~ ~~Effect~~(107,964) of(107,964) ~~foreign~~Subscriptions ~~currency~~receivable ~~translation~~-- ~~adjustment~~-- -- (942,974) (942,974) Accumulated other comprehensive loss -- -- -- (9416,035) (16,035) ---------- ---------- ---------- ---------- ---------- ~~Net~~Total ~~increase~~shareholders' equity -- -- -- (~~decrease~~131,675) (131,675) (Investment in) ~~cash~~/ ~~and~~net ~~cash~~equity ~~Equivalents~~of ~~1,036~~Guarantor subsidiaries (4980,210) ~~987~~ -- ~~987~~(80,210) ~~Cash~~80,210 ~~and~~-- ~~cash~~(Investment ~~equivalents~~in) at/ ~~beginning~~net equity of ~~period~~Non-guarantor ~~474~~subsidiaries 3(11,~~566~~833) 411,~~040~~833 -- ~~4,040~~-- -- ---------- ---------- ---------- ---------- ---------- ~~Cash~~Total liabilities and ~~cash~~shareholders' ~~equivalents~~equity ~~at end of period~~ $ 1288,~~510~~093 $ 354,~~517~~706 $ 5342,~~027~~799 $ --6,524 $ 5349,~~027~~323 ========== ========== ========== ========== ==========

11 13 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS THREE MONTHS ENDED APRIL 29, 2001

~~BEGINNING~~THREE ~~ENDING~~MONTHS ~~BALANCE~~ENDED ~~FISCAL~~APRIL 29, 2001 ~~FISCAL~~------------------------------------------------------------------------------------------------ ~~2001~~GUARANTOR ~~BALANCE~~NON-GUARANTOR ~~OCTOBER~~ELIMINATING ~~29,~~MAXXIM ~~RECORDED~~GROUP ~~CASH~~PARENT ~~JANUARY~~CONSOLIDATED ~~28,~~SUBSIDIARIES ~~2000~~SUBSIDIARIES ~~EXPENSES~~ENTRIES ~~PAYMENTS~~TOTAL ~~2001~~GUARANTOR TOTAL ------------ ------------- ----------- ------------ ~~(IN~~--------- ~~THOUSANDS)~~------------ ~~Severance~~Net sales $ 2121,~~211~~162 $ 17,980 $ (4,843) $ 134,299 $ -- $ ~~669~~134,299 $1Cost of sales 92,~~542~~290 ~~Termination~~14,736 ~~benefits~~(4,843) ~~410~~102,183 -- 76102,183 ~~334~~---------- ~~Plant~~-------- ~~closure~~-------- ~~expenses~~---------- 1-------- ---------- Gross profit 28,~~523~~872 3,244 -- ~~262~~32,116 1-- 32,~~261~~116 ---------- -------- -------- ---------- -------- ---------- Selling, general and administrative 20,242 2,992 -- 23,234 -- 23,234 ---------- -------- -------- ---------- -------- ---------- Income from operations 8,630 252 -- 8,882 -- 8,882 Interest (expense), net (10,400) (526) -- (10,926) (2,129) (13,055) Other income/(expense), net (855) 19 -- (836) -- (836) ---------- -------- -------- ---------- -------- ---------- Net loss $ 4(2,~~144~~625) $ (255) $ -- $ 1(2,~~007~~880) $3 (2,~~137~~129) $ (5,009) ========== ======== ======== ========== ======== ==========

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS THREE MONTHS ENDED APRIL 30, 2000 THREE MONTHS ENDED APRIL 30, 2000 ------------------------------------------------------------------------------------------------- GUARANTOR NON-GUARANTOR ELIMINATING MAXXIM GROUP PARENT CONSOLIDATED SUBSIDIARIES SUBSIDIARIES ENTRIES TOTAL GUARANTOR TOTAL ------------ ------------- ----------- ------------ ---------- ------------ Net sales $ 119,075 $ 22,093 $ (10,408) $ 130,760 $ -- $ 130,760 Cost of sales 92,309 19,320 (10,408) 101,221 -- 101,221 ---------- ---------- ---------- ---------- ---------- ---------- Gross profit 26,766 2,773 -- 29,539 -- 29,539 ---------- ---------- ---------- ---------- ---------- ---------- Selling, general and Administrative 21,350 3,915 -- 25,265 -- 25,265 Restructure and transition Expenses 833 -- -- 833 -- 833 ---------- ---------- ---------- ---------- ---------- ---------- 22,183 3,915 -- 26,098 -- 26,098 ---------- ---------- ---------- ---------- ---------- ---------- Income (loss) from operations 4,583 (1,142) -- 3,441 -- 3,441 Interest (expense), net (9,701) (552) -- (10,253) (1,893) (12,146) Other income/(expense), net (1,971) (129) -- (2,100) -- (2,100) Recapitalization expenses (201) -- -- (201) -- (201) ---------- ---------- ---------- ---------- ---------- ---------- Loss before income taxes (7,290) (1,823) -- (9,113) (1,893) (11,006) Income tax benefit (2,376) (605) -- (2,981) (738) (3,719) ---------- ---------- ---------- ---------- ---------- ---------- Net loss $ (4,914) $ (1,218) $ -- $ (6,132) $ (1,155) $ (7,287) ========== ========== ========== ========== ========== ==========

12 14 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS SIX MONTHS ENDED APRIL 29, 2001

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS SIX MONTHS ENDED APRIL 30, 2000

13 15 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED APRIL 29, 2001

14 16 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED APRIL 30, 2000

15 17 MAXXIM MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED) (UNAUDITED) NOTE 10 -RESTRUCTURE CHARGES AND TRANSITION EXPENSES Through April 29, 2001 we have separated approximately 448 employees relating to the restructuring charges taken in fiscal 2000. The remaining severance benefits of $418,000 will be paid in accordance with plan provisions.

16 18 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION. The following discussion should be read in conjunction with the Condensed Consolidated Financial Statements and related Notes appearing elsewhere in this report. RESULTS OF OPERATIONS The following table sets forth, for the periods indicated, the percentage which selected items in the Condensed Consolidated Statements of Operations bear to net sales:

Net sales - Net sales for the second fiscal quarter of 2001 were $134.3 million compared to $130.8 million in the second fiscal quarter of 2000. The 2.7% increase in sales quarter over quarter is primarily the result of the following factors: an increase in custom procedure tray sales to $82.7 million for the second quarter of fiscal 2001 from $77.1 million for the second quarter of fiscal 2000 due to sales conversions from a large group purchasing organization contract obtained in fiscal 2000; a slight decline in medical glove sales to $21.2 million in the second quarter of fiscal 2001 from $21.8 million in the comparable quarter of fiscal 2000; and a decline in all our other product sales to $30.4 million in the second quarter of fiscal 2001 from $31.9 million in the second quarter of fiscal 2000. Net sales for the six months ended April 29, 2001 were $257.8 million compared to $253.6 million in the first six months of fiscal 2000. The 1.7% increase in sales period over period is primarily the result of the following factors: an increase in custom procedure tray sales to $158.1 million for the six months ended April 29, 2001 from $146.6 million in the comparable period of fiscal 2000 due to sales conversions from a large group purchasing organization contract obtained in fiscal 2000; a decline in medical glove sales to $42.0 million in the six months ended April 29, 2001 from $45.3 million in the comparable period of fiscal 2000 primarily caused by lower O.E.M. sales; and a decline in all our other product sales to $57.7 million in the six months ended April 29, 2001 from $61.7 million in the comparable period of fiscal 2000. 17 19 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION - (CONTINUED) Gross profit - Gross profit increased to $32.1 million or 23.9% of net sales in the second quarter of fiscal 2001 from $29.5 million or 22.6% of net sales reported in the second quarter of fiscal 2000. For the six month period ended April 29, 2001, gross profit was $61.8 million or 24.0% of net sales in fiscal 2001 versus $59.5 million or 23.5% of net sales in the comparable period of fiscal 2000. Gross profit for fiscal 2001 was negatively impacted by costs associated with the plant rationalization program that began in the fourth quarter of fiscal 2000. The negative impact on the fiscal 2001 first quarter gross profit was $2.1 million and $1.5 million in the second quarter. Gross profit for fiscal 2000 was negatively impacted by a strike and a facility rationalization program in our glove business. The negative impact on the fiscal 2000 first quarter gross profit was $2.9 million of which $1.8 million was a non-cash inventory write-down. The negative impact on the fiscal 2000 second quarter gross profit was $4.3 million of which $1.2 million related to the strike which ended in May with the signing of a new collective bargaining agreement. Excluding these one-time items, we experienced a period over period decline in custom procedure tray margin primarily caused by the pricing terms of a large group purchasing organization contract obtained in fiscal year 2000. Selling, general and administrative expenses - Selling, general and administrative expenses declined to $23.2 million or 17.3% of net sales in the second quarter of fiscal 2001 from $25.3 million or 19.3% of net sales in the second quarter of fiscal 2000. For the six month period ended April 29, 2001, selling, general and administrative expenses declined to $44.8 million or 17.4% of net sales in fiscal 2001 from $47.8 million or 18.8% of net sales in the comparable period of fiscal 2000. This improvement in selling, general and administrative expenses quarter over quarter as well as period over period is attributable to improvements in sales, marketing and distribution expenses combined with general cost reductions. Restructure charges and transition expenses - In the first six months of fiscal 2000, we recorded charges of $0.3 million in severance costs and $1.4 million of other transition expenses related to the closing of one of our glove plants. Income from operations - Income from operations for the second quarter of fiscal 2001 was $8.9 million or 6.6% of net sales, compared to $3.4 million or 2.6% of net sales in the second quarter of fiscal 2000. Income from operations for the six months ended April 29, 2001 was $17.0 million or 6.6% of net sales, compared to $10.1 million or 4.0% of net sales in the comparable period of fiscal 2000. Interest expense - Interest expense increased to $13.1 million in the second quarter of fiscal 2001 from $12.1 million reported in the second quarter of fiscal 2000. Interest expense increased to $27.2 million in the six months ended April 29, 2001 from $23.4 million reported in the comparable period of fiscal 2000. The Company incurred cash interest expense of $8.4 million and $8.7 million in the quarters ended April 29, 2001 and April 30, 2000, respetively. In the six months ended April 29, 2001 and April 30, 2000, the Company incurred $18.9 million and $17.2 million of cash interest expense respectively. The increased interest expense period over period is primarily a function of the marking to market of the Company's derivative securities and a full period's interest expense and amortization on the debt incurred with the recapitalization. Recapitalization expenses - Recapitalization expenses of $18.9 million were recorded in the first half of fiscal 2000 due to the recapitalization of Maxxim on November 12, 1999. The recapitalization expenses include approximately $14.0 million of professional fees. Income taxes - The Company has determined that it is more likely than not that future operations will not generate sufficient taxable income to realize tax loss carryovers and other deferred tax assets. As a result, the Company has recorded a full valuation allowance on tax benefits generated for the quarter and the six months ended April 29, 2001. Our effective tax rate for the six months ended April 30, 2000 was a benefit of 20.0%. The tax benefit rate for April 30, 2000 is lower than the statutory rate due to nondeductible goodwill amortization and recapitalization expenses. Loss from continuing operations - As a result of the foregoing, we reported a loss from continuing operations of $5.0 million in the second quarter of fiscal 2001 versus $7.3 million in the second quarter of fiscal 2000. We reported a loss from continuing operations of $11.8 million in the six months ended April 29, 2001 versus $27.7 million in the comparable period of fiscal 2000. Discontinued operations - In connection with the recapitalization, all of the outstanding stock of Circon was sold to Circon Holdings in exchange for $208.0 million in cash and the repayment of $20.0 million of debt owed by Circon to Maxxim. Accordingly, Circon's operations have been reflected as discontinued operations in our condensed consolidating statements of operations. In the quarter ended January 30, 2000, we recorded a gain of $87,000 on the sale of Circon. 18 20 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION - (CONTINUED) Extraordinary item - In connection with the recapitalization, we consummated a tender offer for our 10 1/2% senior subordinated notes. Accordingly, the tender premium and deferred debt issuance costs related to these notes were written off as an extraordinary loss in the quarter ended January 30, 2000. Cumulative effect of change in accounting principle - In the quarter ended January 28, 2001, the Company implemented FASB 133. As a result, a loss was recorded to reflect a derivative instrument at its fair value at October 30, 2000. Net loss - As a result of the foregoing, we reported a loss of $5.0 million for the second quarter of fiscal 2001 versus $7.3 million in the second quarter of fiscal 2000. We reported a loss of $12.1 million for the six months ended April 29, 2001 versus $38.7 million in the comparable period of fiscal 2000. LIQUIDITY AND CAPITAL RESOURCES Net cash provided by operating activities was $1.1 million in the six months ended April 29, 2001 versus $6.9 million in the comparable period of fiscal 2000. Net cash from operating activities was negatively impacted in the first half of fiscal 2001 due to an increase in accounts receivable and inventory which was somewhat offset by an increase in accounts payable and the receipt of an income tax refund. Net cash from operating activities was negatively impacted in first half of fiscal 2000 due to increases in inventory, accounts receivable, and income tax receivable and a decline in accrued expenses. Cash flows used by investing activities were $1.7 million in the first half of fiscal 2001 while cash flows generated in investing activities were $222.8 in the first half of 2000. The sale of Circon as part of the recapitalization provided $228 million in the first quarter of fiscal 2000. Capital expenditures totaled $2.0 million and $4.9 million in first half of fiscal 2001 and 2000, respectively. Cash flows provided from financing activities was $1.7 million in the first half of fiscal 2001 while cash flows used in financing activities was $225.6 million in the first half of fiscal 2000. In the six months ended April 30, 2000 Maxxim or its subsidiaries received the following proceeds as a result of the recapitalization: $50.0 million from the issuance of senior discount notes, $110.0 million from the issuance of senior subordinated discount notes and $260.0 million from a new credit facility. Then, as part of the recapitalization, these funds were used to pay the following debts in the first quarter of fiscal 2000: $100.0 million for Maxxim's 10 1/2% senior subordinated notes, $254.0 million for the outstanding balance on Maxxim's previous credit facility, $20.6 million for debt offering costs and $37.0 million for debt tender and recapitalization expenses. In addition, the net impact from the repurchase of outstanding stock and options and proceeds from the issuance of new common stock in accordance with the provisions of the recapitalization was the payment of $232.4 million in the six months ended April 30, 2000. At April 29, 2001, our balance sheet included net goodwill of $109.0 million. The majority of this balance represents goodwill from the acquisitions of Winfield Medical and Sterile Concepts. Maxxim acquired Winfield Medical in June 1998. Unamortized goodwill from the Winfield acquisition totaled $21.5 million at April 29, 2001, which represents 19.7% of net goodwill on that date. In July 1996, Maxxim acquired Sterile Concepts. Unamortized goodwill from the Sterile Concepts acquisition totaled $75.8 million at April 29, 2001, and represented 69.6% of net goodwill as of that date. The remaining $11.7 million of unamortized goodwill at April 29, 2001, relates to various other acquisitions made between 1992 and 2000. All components of goodwill are being amortized on a straight line basis over the applicable useful life. Useful lives have been estimated at 30 years for Winfield Medical, 40 years for Sterile Concepts and 5 to 20 years for the remaining goodwill components. Total goodwill amortization expense for the six months ended April 29, 2001, and April 30, 2000, were $2.1 million and $2.6 million, respectively. Management believes that there is not persuasive evidence that any material portion of this intangible asset will dissipate over a period shorter than the determined useful life. 19 21 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION - (CONTINUED) The revolving credit facility is available for general corporate purposes, including working capital and capital expenditures, and includes sublimits of $25.0 million and $10.0 million, respectively, for letters of credit and swingline loans. At April 29, 2001, the Company had $7.0 million drawn under its revolving credit facility. The credit facilities and the terms of our senior subordinated discount notes impose certain restrictions on us and our subsidiaries, including restrictions on our ability to incur additional indebtedness, issue preferred stock, pay dividends and make certain distributions, make investments, sell assets, create liens, enter into certain transactions with affiliates and engage in certain other activities. In addition, the credit facilities require us to maintain certain financial ratios. The credit facilities are secured by substantially all of our assets, including real and personal property, inventory, accounts receivable and other intangibles, in each case subject to certain limited exceptions. Our ability to satisfy our debt obligations and to pay principal and interest on debt, fund working capital and make anticipated capital expenditures will depend on our future performance, which is subject to general economic, financial and other factors, some of which are beyond our control. We believe that based on current levels of operations and anticipated growth, cash flow from operations, together with borrowings under the revolving credit facility, will be adequate for the foreseeable future to make required payments of principal and interest on our debt, to fund working capital, and to make expected capital expenditures. There can be no assurance, however, that our business will generate sufficient cash flow from operations or that future borrowings will be available under the revolving credit facility in an amount sufficient to enable us to service our debt, or to fund other liquidity needs. Forward looking statements This report contains forward looking statements. Forward looking statements are statements of our expectations, estimates, projections and beliefs and are based on assumptions made by and information currently available to us regarding our business and the industry in which we operate. Forward-looking statements describe our expectations today of what we believe is most likely to occur or reasonably achievable in the future, but such statements do not predict or assure any future occurrence and may turn out to be wrong. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. The words "believe," "anticipate," "intend," "expect," "estimate," "project", "predict", "hope" and "should", variations of such words, and similar expressions, among others, are intended to identify forward-looking statements. Forward looking statements are subject to potential risks and uncertainties that could cause actual results to differ materially from historical results or those currently anticipated. The potential risks and uncertainties that could affect forward looking statements are listed within our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 14, 2001. We caution that undue reliance should not be placed on our forward-looking statements, which speak only as of the date of this document. We hereby disclaim any obligation to update information contained in any forward-looking statement. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to market risks. Market risk is the potential loss arising from adverse changes in market prices, interest rates and foreign currency exchange rates. Interest Rate Risk --We are subject to market risk exposure related to changes in interest rates on the new credit facilities. Interest on borrowings under the new credit facilities are at a fixed percentage point spread from either (1) the greater of prime, base CD or federal funds rates or (2) LIBOR. We are able to, at our option, fix the interest rate for LIBOR for periods ranging from one to six months. The interest rate on all outstanding obligations under the new credit facility are currently set off three month LIBOR. We have entered into, and are required to maintain for at least three years, one or more interest rate protection agreements in order to fix or limit our interest costs with respect to at least 50% of the outstanding term loans under the new credit facilities. In accordance with the obligations of our credit facility, we and the Chase Manhattan Bank entered into an arrangement to cap our floating interest rate at 8.0% on an agreed upon notional principal amount of $130,000,000, in April 2000. 20 22 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK- (CONTINUED) Foreign Currency Exchange Rate Risk -- Generally we generate net sales and expenses in the local currency where our products are sold and thus are not currently subject to significant currency exchange risk. In the future, it is possible that a greater portion of our net sales outside of North America may not be denominated in the same local currency as the related expenses and thus we may be subject to currency exchange risks in connection therewith. Intangible Asset Risk - Our balance sheet includes intangible assets. We assess the recoverability of intangible assets by determining whether the amortization of the asset balance over its remaining life can be recovered through undiscounted future operating cash flows of the acquired operation. The amount of asset impairment, if any, is measured based on projected discounted future operating cash flows using a discount rate reflecting our average cost of funds. In fiscal 2000, we recorded goodwill and other intangible asset impairments of $33.5 million. We do not believe that any other impairment of intangible assets existed as of April 29, 2001. PART II. OTHER INFORMATION Items 1, 2, 4 and 5 for which provision is made in the applicable regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and therefore have been omitted. Item 3. LEGAL PROCEEDINGS Other litigation- In September 2000, certain former employees brought a lawsuit in state court in Florida. The plaintiffs therein allege various common law and statutory causes of action arising out of the termination of their employment following our November 1999 recapitalization. A related lawsuit based on the same events has been brought in state court in Harris County, Texas by one of our directors. We have denied the allegations of these lawsuits and have moved successfully to stay the Florida action and to compel arbitration of the underlying dispute, as is required by the former employees' employment agreements with the Company. Item 6. EXHIBITS AND REPORTS (a) Exhibits None. (b) Reports on Form 8-K None. 21 23 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MAXXIM MEDICAL, INC. Date: 6/13/01 By: /s/ Akbar Naderi ----------- -------------------------------------------- Akbar Naderi Vice Chairman and President (principal executive officer) Date: 6/13/01 By: /s/ Mark S. Sellers ----------- -------------------------------------------- Mark S. Sellers Vice Chairman and Chief Financial Officer (principal financial officer) 22

Filing Compare · MEDICAL WIND DOWN HOLDINGS I INC